CTOs on the Move

Executive Network Enterprises

www.executivenetworkenterprises.com

 
Executive Network Enterprises is a Santa Monica, CA-based company in the Consumer Services sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Curebit Inc

Curebit Inc is a San Francisco, CA-based company in the Consumer Services sector.

Harris, Finley, and Bogle

Harris, Finley, and Bogle is a Fort Worth, TX-based company in the Consumer Services sector.

Keeny Joyner And Associates

Keeny Joyner And Associates is a Rocky Mount, NC-based company in the Consumer Services sector.

Securitas Critical Infrastructure Services

Securitas Critical Infrastructure Services Inc. (SCIS) is one of the largest providers in the United States of specialized security, fire and emergency response services to meet federal government security requirements in the Aerospace/Defense, Energy,...

Flamel

Flamel Technologies SA is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently has approvals for and markets two previously Unapproved Marketed Drugs ("UMDs") in the USA, Bloxiverz® (neostigmine methylsulfate injection) and Vazculep® (phenylephrine hydrochloride injection). The Company intends to add to this branded business by creating additional products, focusing on the development of products utilizing Flamel`s proprietary drug delivery platforms, and recently announced FDA acceptance of its third NDA filing with an FDA-assigned PDUFA date of April 30, 2016. Flamel also has several products in development utilizing Micropump® (oral sustained release microparticles platform) along with its tangent technologies, LiquiTime® and Trigger Lock™. The lead project for Micropump® is sodium oxybate. LiquiTime® allows for the extended-release of liquid medicines (such as ibuprofen and guaifenesin) and Trigger Lock™ is an abuse-resistant iteration of Micropump®, designed specifically for long-acting opioids (such as hydromorphone). Additionally, the Company has developed a long acting injectable platform, Medusa™, a hydrogel depot technology currently being studied with exenatide. Flamel`s products are targeting high-value molecules and will utilize either the 505(b)(2) approval process for NDAs or biosimilar pathways ultimately approved by FDA and other regulatory authorities. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and Dublin, Ireland.